Market Insights

The Rheumatoid Arthritis Treatment Market was estimated at US$ 23.1 billion in 2020 and is expected to grow at a CAGR of 6% during 2021-2026 to reach US$ 32.7 billion by 2026.

Wish to get a free sample? Register here

What is Rheumatoid Arthritis?

Rheumatoid Arthritis is an autoimmune and chronic inflammatory disorder that affects the joints. It can also damage other parts of the body including skin, lungs, heart, eyes, and blood vessels. It happens when the immune system attacks the body tissues by mistake and thus, causes inflammation in the joints.

Market Dynamics

The growth of the global rheumatoid arthritis treatment market is primarily driven by the increasing prevalence of arthritis particularly among the geriatric populace across geographies.

• Increasing consumer awareness is expected to bolster market growth significantly.

• Additionally, the growing emphasis on the development of advanced solutions by the market players is projected to propel market growth at a significant rate during the review period.

• However, the high cost associated with rheumatoid arthritis treatment is likely to affect the market growth.

COVID-19 Impact

The COVID-19 outbreak did affect the growth of the rheumatoid arthritis treatment market negatively due to fear among people that patients having rheumatoid arthritis are more prone to COVID-19 and are likely to face more severe complications. The rheumatoid arthritis patients made significant changes in their medical use amid the COVID-19 outbreak and thus, affected the market growth.

Segments Analysis

Therapy Type Trends

The rheumatoid arthritis market has been segmented into symptomatic treatment, intermediate corticosteroid therapies, and disease-modifying antirheumatic drug (DMARD) therapies.

• The DMARD segment has been further bifurcated into conventional DMARDs and biologic DMARDs.

• The DMARD segment accounted for the largest market share in 2020 and is projected to grow at the fastest CAGR during the review period due to the increasing adoption of conventional DMARD therapy to treat rheumatoid arthritis.

Regional Analysis

Geographically, the market in North America accounted for the largest market share during the forecast period.

• The market growth can be attributed to the expanding geriatric populace and the availability of advanced healthcare infrastructure.

• The market in Asia-Pacific is expected to register the fastest growth during the review period on account of rising consumer awareness and the growing medical tourism industry in developing countries.

Want to know which region offers the best growth opportunities? Register Here

Key Players

The market is highly populated with the presence of several local, regional, and global players. Most of the major players compete in some of the governing factors including price, product offerings, regional presence, etc.

The following are the key players in the global rheumatoid arthritis treatment market (arranged alphabetically).

• AbbVie Inc. (The U.S),
• Amgen Inc. (The U.S),
• Bristol-Myers Squibb Company (The U.S),
• Eli Lilly & Company (The U.S),
• F. Hoffman-La Roche AG (Switzerland),
• Johnson & Johnson (The U.S),
• Pfizer Inc. (The U.S),
• Sanofi SA (France),
• Sobi Inc. (Sweden),
• UCB S.A. (Belgium).

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at [email protected]

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Target Audience

Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

• Manufacturers
• Suppliers
• Distributors
• Organizations
• Government bodies

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. 

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Option

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players).
• SWOT analysis of key players (up to three players).

Competitive Benchmarking

• Benchmarking of key players on the following parameters: product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected].